Small Cap Feast

31st October 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 
Dish Of The Day:

Joiners: 
No joiners today.

Leavers: 
Osirium Technologies Plc (OSI.L) has left AIM.





What’s Cooking In The IPO Kitchen?

Tekcapital announced intention to spin off and IPO on 2 October: MicroSalt, the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. AIM Admission delayed, expected mid-November.


Breakfast Buffet

Acuity RM Group 4.75p £5.8m (ACRM.L)
A provider of risk management services through its STREAM® software platform announces that its wholly owned operating subsidiary, Acuity Risk Management Limited (Acuity), has won a new three year contract worth £160k, for the use of STREAM® by a new client to manage their ISO 27001 framework and excellence of service. The contract was won in conjunction with a new partner with worldwide operations.

Artemis Resources 1.23p £20.5m (ARV.L)
The Australian-based mining exploration and development company, announces that George Jerry Ventouras has been appointed as an Executive Director of the Company with immediate effect. George is currently a Non-Executive Director of Errawarra Resources Ltd. Previously, he was joint-founder, non-executive director and General Manager of Apollo Consolidated Ltd. Mr Daniel Smith has resigned as a director as of today's date.

Brand Architekts Group 27.5p £7.7m (BAR.L)
The Company focusing in the development and supply of beauty and personal care brands, announces its full year results to 30 June 2023. Group sales of £20.1m (2022: £14.3m) up 41% primarily due to the acquisition of InnovaDerma Plc, which completed at the end of May 2022. Underlying gross profit margins increased by 6.2% to 39.7% (2022: 33.5%) and the Group generated a reduced underlying operating loss of £1.2m (2022: £1.8m). The Group has a net cash position of £8.2m at the year-end. The integration of Innovaderma into the Group delivered £1.4m of ongoing Opex savings and the Group is confident in achieving their medium and long term goals.

Chariot Oil & Gas 14.09p £150.8m (CHAR.L)
The Africa focused transitional energy group, announces that it has received approval for its Environmental Impact Assessment (EIA) from the Moroccan Ministry of Energy Transition and Sustainable Development on the Anchois gas development project (Anchois) offshore Morocco. The final report sets out the requisite planning, mitigation and monitoring measures to follow during construction and production. The EIA integrates recommendations from the National Environmental Committee, is valid for five years and covers all aspects of the development including future wells and offshore infrastructure, the onshore Central Process Facility and link to the GME pipeline.

essensys 28.5p £18.4m (ESYS.L)
The provider of software and technology to the flexible workspace industry, announces its audited results for the financial year ended 31 July 2023. Group total revenues up 9% to £25.3m (FY22: £23.3m) driven by new site activity, as a result adjusted EBITDA loss decreased by 10% to £6.3m (FY22: loss £7.0m). The Group remains debt-free with cash balance of £7.9m. Additional £2m unsecured loan facility provided by Mark Furness, the Group CEO and largest shareholder. Strategic customers now account for 77% of Group revenue (FY22: 72%) with 21 new customers signed in the period. The Group are on track to return to run-rate positive Adjusted EBITDA in FY24 and net cash generation in FY25.

Frontier IP Group 41.5p £23.1m (FIPP.L)
A Company focusing in commercialising intellectual property, announces that Andrew Richmond, currently Non-Executive Chairman, will be stepping down from the board of Frontier IP at the Company’s next annual general meeting expected to be in December 2023. Dame Julia King, Baroness Brown of Cambridge, who is currently the Senior Independent Director on the board, will assume the role of Chair with effect from the conclusion of the forthcoming AGM.

Kore Potash 0.4p £14.3m (KP2.L)
The potash development company with 97% ownership of the Kola and DX Potash Projects in the Sintoukola Basin, located in the Republic of Congo, announce the successful completion of a share subscription (Fundraise), which has raised US$ 2.5m through the proposed issue new ordinary shares at a price of 0.38 pence per share the (Subscription Price). The Subscription price is at a 30.9% discount to the close price of 0.55 pence as at 30 October 2023. Gross proceeds will be used to further advance work that is expected to lead to the delivery of an EPC contract for the Kola Potash Project, and for working capital.

Kromek Group 4.8p £28.8m (KMK.L)
A developer of radiation and bio-detection technology solutions for the imaging and CBRN detection segments, announces that it has secured three further orders totalling over $1m in the CBRN detection segment. This includes two orders in nuclear security, with one order for the further development of the Group's bio-security technology. The majority of the revenue will be recognised in the current financial year.

Scancell Holdings 12.5p £102.5m (SCLP.L)
The developer of immunotherapies for the treatment of cancer and infectious disease, announces its final audited financial results for the year ended 30 April 2023. Operating loss of £11.9m (30 April 2022: operating loss of £13.3m), Group cash balance at 30 April 2023 was £19.9m (30 April 2022: £28.7m) with a cash runway through to early 2025. SCIB1 reported positive data from the first stage of its Phase 2 SCOPE trial for advanced melanoma. Modi-1 has completed dose escalation and safety cohorts of the Phase 1/2 ModiFY trial and is now into expansion cohorts. The Company is confident it will achieve its near-term clinical milestones.

Strip Tinning Holdings 42.5p £6.6m (STG.L)
A supplier of specialist connection systems to the automotive sector, provides an update on trading covering the period 1 July to 30 September 2023 (Q3). Year-to-date revenues of £8.2m (Q3 YTD FY22: £8.0m) and a positive adjusted EBITDA performance. The Company further announce that it has secured a £166k grant from the Advanced Propulsion Centre UK Feasibility Studies competition. Trading in Q3 of the financial year ending 31 December 2023 (FY23) has been in line with management's expectations and the Board expects to meet FY23 market guidance.

31 October 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram